Essex Bio-Technology (SEHK:1061) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

1061 Aktienübersicht

Essex Bio-Technology Limited, eine Investment-Holdinggesellschaft, entwickelt, produziert, vertreibt und verkauft biopharmazeutische Produkte in der Volksrepublik China, in Hongkong und international.

Über das Unternehmen

1061 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	4/6
Financial Health	6/6
Dividends	4/6

Belohnungen

Das Kurs-Gewinn-Verhältnis (5.2x) liegt unter dem Hong Kong Markt (9.8x)

Die Erträge stiegen im vergangenen Jahr um 22.1%

Risikoanalyse

Unbeständige Dividendenentwicklung

Essex Bio-Technology Limited Wettbewerber

Uni-Bio Science Group

SEHK:690

HK$400.6m

HBM Holdings

SEHK:2142

HK$1.0b

3SBio

SEHK:1530

HK$15.0b

Shanghai Haohai Biological Technology

SEHK:6826

HK$14.7b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Essex Bio-Technology
Historical stock prices
Current Share Price	HK$2.55
52 Week High	HK$3.64
52 Week Low	HK$1.96
Beta	0.26
1 Month Change	7.14%
3 Month Change	19.72%
1 Year Change	-23.88%
3 Year Change	-62.44%
5 Year Change	-64.08%
Change since IPO	157.58%

Aktuelle Nachrichten und Updates

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

May 06

Recent updates

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23

Aktionärsrenditen

	1061	HK Biotechs	HK Markt
7D	-0.4%	0.3%	-0.1%
1Y	-23.9%	-34.3%	0.02%

Rendite im Vergleich zur Industrie: 1061 übertraf die Branche Hong Kong Biotechs, die im vergangenen Jahr eine Rendite von -35.8 erzielte.

Rendite vs. Markt: 1061 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von 2.7 erzielte.

Preisvolatilität

Is 1061's price volatile compared to industry and market?
1061 volatility
1061 Average Weekly Movement	5.4%
Biotechs Industry Average Movement	9.1%
Market Average Movement	7.3%
10% most volatile stocks in HK Market	15.7%
10% least volatile stocks in HK Market	3.7%

Stabiler Aktienkurs: 1061 hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: 1061Die wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1990	1,481	Haizhou Fang	www.essexbio.com

Essex Bio-Technology Limited, eine Investment-Holding, entwickelt, produziert, vertreibt und verkauft biopharmazeutische Produkte in der Volksrepublik China, Hongkong und international. Das Unternehmen ist in den Segmenten Ophthalmologie und Chirurgie tätig. Es erforscht und entwickelt therapeutische Fibroblasten-Wachstumsfaktor-Produkte für die Behandlung von Zellproliferation, Differenzierung und Migration.

Essex Bio-Technology Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Essex Bio-Technology im Vergleich zum Marktanteil des Unternehmens?
1061 grundlegende Statistiken
Marktanteil	HK$1.45b
Gewinn(TTM)	HK$275.26m
Umsatz(TTM)	HK$1.71b

5.3x

Kurs-Gewinn-Verhältnis

0.8x

Kurs-Umsatz-Verhältnis

Ist 1061 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
1061 Gewinn- und Verlustrechnung (TTM)
Einnahmen	HK$1.71b
Kosten der Einnahmen	HK$167.26m
Bruttogewinn	HK$1.54b
Sonstige Ausgaben	HK$1.26b
Umsatz	HK$275.26m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.49
Bruttomarge	90.20%
Nettogewinnspanne	16.13%
Schulden/Eigenkapital-Verhältnis	14.1%

Wie hat sich 1061 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

3.5%

Aktuelle Dividendenrendite

19%

Ausschüttungsquote

1061 Aktienübersicht

Belohnungen

Risikoanalyse

Essex Bio-Technology Limited Wettbewerber

SEHK:690

HK$400.6m

SEHK:2142

HK$1.0b

SEHK:1530

HK$15.0b

SEHK:6826

HK$14.7b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Recent updates

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

Investor sentiment deteriorates as stock falls 16%

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.045 per share at 2.0% yield

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative (Wet) Age-Related Macular Degeneration

Less than half of directors are independent

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 1.8% yield

Now 21% undervalued after recent price drop

Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Price target decreased to HK$6.00

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Upcoming dividend of HK$0.04 per share

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

First half 2022 earnings released: EPS: HK$0.24 (vs HK$0.28 in 1H 2021)

Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021

Price target increased to HK$7.00

Less than half of directors are independent

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.04 per share

First half 2021 earnings released: EPS HK$0.28 (vs HK$0.085 in 1H 2020)

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021 at the Annual General Meeting held on May 12, 2021

Upcoming dividend of HK$0.05 per share

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology Limited Announces Dividend for the Year Ended December 31, 2020, Payable on 1 June 2021

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

Full year 2020 earnings released: EPS HK$0.38 (vs HK$0.52 in FY 2019)

Essex Bio-Technology Limited to Report Fiscal Year 2020 Results on Mar 12, 2021

Investor sentiment improved over the past week

Essex Bio-Technology Limited Announces Positive Outcome of U.S. FDA Second Phase 3 Clinical Trial in Dry Eye Disease

New 90-day high: HK$4.85

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Investor sentiment improved over the past week

Erträge & Einnahmen